Mistral Pharma Inc. Launches INSTILLAGEL(R) on the Canadian Market
Published: Nov 01, 2007
MONTREAL, QUEBEC--(Marketwire - November 01, 2007) - Mistral Pharma Inc. (TSX VENTURE: MIP) ("Mistral") today announced that it is launching INSTILLAGEL® on the Canadian market. INSTILLAGEL® is now available to all urology clinics, hospitals and pharmacies across Canada. INSTILLAGEL® is a sterile gel containing lidocaine 2% and chlorhexidine 0,05% and is indicated for surface anaesthesia, lubrication and antisepsis for the male and female urethra during cytoscopy, catheterization, exploration by sound and other endourethral operations.